We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam Commences Phase III Study for Hemophilia Candidate
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) and Sanofi’s (SNY - Free Report) announced that it has commenced phase III ATLAS study for its candidate fitusiran. Fitusiran is an investigational RNA interference (RNAi) therapeutic being developed for the treatment of hemophilia and rare bleeding disorders (RBD).
Shares of the company have outperformed the Zacks classified Medical - Biomedical and Genetics industry so far this year. The stock has soared 124.5%, while the industry gained 7%.
The phase III study will assess the safety and efficacy of fitusiran in three separate trials, including patients with hemophilia A and B with or without inhibitors and patients receiving prophylactic therapy. Two of these studies include ATLAS-INH and ATLAS-A/B, which will include patients with hemophilia A or B with inhibitors receiving prior on-demand therapy. The duration for both these studies will be nine months.
The third study, ATLAS-PPX, will enroll about 100 patients with hemophilia A or B with or without inhibitors receiving prophylaxis therapy as prior standard of care. Top-line data from the ATLAS trials are expected in mid-to-late 2019.
Notably, Alnylam is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference (RNAi). The company’s progress with its pipeline candidates has been impressive. Moving ahead, it expects 2017 to be a pivotal year with its first phase III data read out from the APOLLO study for its late-stage pipeline candidate patisiran.
Additionally, the company plans to advance two additional programs, givosiran and inclisiran, into late-stage trials in 2017. Givosiran is in development for the treatment of acute hepatic porphyrias and inclisiran is being evaluated for the treatment of hypercholesterolemia.
Last week, another pharmaceutical company, Shire plc , announced that it has filed an investigational new drug (IND) application with the FDA, seeking approval for its recombinant factor VIII (FVIII) gene therapy candidate, SHP654, for the treatment of patients with Hemophilia A. The gene therapy developed by the company treats hemophilia A by selectively targeting the liver.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017, and from 11 cents to 3 cents for 2018, over the last 30 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 62.4% year to date.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Alnylam Commences Phase III Study for Hemophilia Candidate
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) and Sanofi’s (SNY - Free Report) announced that it has commenced phase III ATLAS study for its candidate fitusiran. Fitusiran is an investigational RNA interference (RNAi) therapeutic being developed for the treatment of hemophilia and rare bleeding disorders (RBD).
Shares of the company have outperformed the Zacks classified Medical - Biomedical and Genetics industry so far this year. The stock has soared 124.5%, while the industry gained 7%.
The phase III study will assess the safety and efficacy of fitusiran in three separate trials, including patients with hemophilia A and B with or without inhibitors and patients receiving prophylactic therapy. Two of these studies include ATLAS-INH and ATLAS-A/B, which will include patients with hemophilia A or B with inhibitors receiving prior on-demand therapy. The duration for both these studies will be nine months.
The third study, ATLAS-PPX, will enroll about 100 patients with hemophilia A or B with or without inhibitors receiving prophylaxis therapy as prior standard of care. Top-line data from the ATLAS trials are expected in mid-to-late 2019.
Notably, Alnylam is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference (RNAi). The company’s progress with its pipeline candidates has been impressive. Moving ahead, it expects 2017 to be a pivotal year with its first phase III data read out from the APOLLO study for its late-stage pipeline candidate patisiran.
Additionally, the company plans to advance two additional programs, givosiran and inclisiran, into late-stage trials in 2017. Givosiran is in development for the treatment of acute hepatic porphyrias and inclisiran is being evaluated for the treatment of hypercholesterolemia.
Last week, another pharmaceutical company, Shire plc , announced that it has filed an investigational new drug (IND) application with the FDA, seeking approval for its recombinant factor VIII (FVIII) gene therapy candidate, SHP654, for the treatment of patients with Hemophilia A. The gene therapy developed by the company treats hemophilia A by selectively targeting the liver.
Alnylam Pharmaceuticals, Inc. Price and Consensus
Alnylam Pharmaceuticals, Inc. Price and Consensus | Alnylam Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Alnylam currently carries a Zacks Rank #3 (Hold). A better-ranked health care stock is Enzo Biochem, Inc. (ENZ - Free Report) , which sports Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017, and from 11 cents to 3 cents for 2018, over the last 30 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 62.4% year to date.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>